glp 1 drug history Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment GLP-1 Medications: Everything You Need
Description
15 This retrospective cohort study used the de-identified EHR data, including health care encounters, medication prescriptions, and laboratory measurements
In conclusion, while GLP-1RAs and GLP-1/GIP dual agonists offer significant clinical advantages, ongoing research and vigilant monitoring of their adverse effects and safety are essential for optimizing their therapeutic application.229,230 Conclusion In summary, GLP-1RAs and dual-receptor agonists targeting both GLP-1 and GIP receptors have introduced significant advancements in the management of endocrine and metabolic disorders and their associated complications, establishing themselves as central therapeutic modalities within this domain
When GLP-1 spending spikes by hundreds of millions of dollars, that cost does not disappear
Competing Interests Blair Suter, Allison Bigeh, Timothy Frommeyer, and Laxmi Mehta declare that they have no conflicts of interest
Conclusion and challenges GLP-1RAs have been used to treat T2DM since 2005 and gained approval for weight management in 2014
